secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRISTOL MYERS SQUIBB CO (BMY)
CIK:        0000014272
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001140361-23-009050
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Bristol-Myers reports no CVR payment due for Abraxane 2022 net sales of $909M
-----------------------------------------------------------------------------

- 2022 Abraxane net sales of $908,974,933 triggered no payment under Celgene CVR agreement.
- Company notified trustee on Feb 23, 2023; no Net Sales Payment due per CVR terms.
- CVR relates to Celgene acquisition from Nov 2019; future payments may be disclosed on BMS website.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/14272/000114036123009050/0001140361-23-009050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/14272/000114036123009050/brhc10048710_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-009050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer